Pelvic Congestion Syndrome Treatments — CPB 0441 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0441 covering pelvic congestion syndrome treatments, effective September 26, 2025. Billing teams need to verify two hard criteria before submitting claims for gonadal vein embolization under CPT 37241 and related codes.

Aetna's pelvic congestion syndrome coverage policy under CPB 0441 Aetna system sets specific medical necessity criteria for embolization procedures billed under CPT codes 36245, 36246, 36247, 36248, 37241, 75894, and 75898. Miss either criterion and the claim lands in denied status — and Aetna's language is unambiguous: procedures that don't meet both requirements are classified as experimental, investigational, or unproven. Here's what your billing team needs to know before the effective date of September 26, 2025.

Aetna Pelvic Congestion Syndrome Coverage Criteria and Medical Necessity Requirements 2025

Aetna's coverage policy for pelvic congestion syndrome embolization rests on two criteria. Both must be met. There's no flexibility here.

Criterion one: The member must have a definitive diagnostic study — venography, CT, or MRI. A clinical exam alone doesn't satisfy this. The imaging must confirm pelvic congestion syndrome before any embolization proceeds.

Criterion two: The member must have tried and failed appropriate pharmacotherapy. That means analgesics, hormonal therapy, or both. No documented failed medical treatment, no covered embolization. This is the criterion most likely to trip up a claim.

When both criteria are met, Aetna considers embolization of gonadal veins, ovarian veins, or internal iliac veins medically necessary. That covers metallic coil embolization and foam or gel sclerotherapy. The procedures can target those vessels individually or in combination.

If your team bills CPT 37241 for vascular embolization, this coverage policy directly controls reimbursement. CPT 37241 is the primary embolization code here — it's inclusive of radiological supervision and interpretation. You'll also commonly bill catheter placement codes 36245, 36246, 36247, and add-on code 36248 alongside it. All of these are covered when selection criteria are met.

Prior authorization requirements aren't explicitly spelled out in the policy language, but given that Aetna classifies non-qualifying cases as experimental, you should treat prior auth verification as standard workflow for every PCS embolization case. Don't let a missing auth be the reason a technically qualifying case gets denied.

Aetna Pelvic Congestion Syndrome Exclusions and Non-Covered Indications

When either of the two medical necessity criteria isn't met, Aetna's position is explicit: the procedure is experimental, investigational, or unproven. This isn't a gray area. Aetna uses that three-part classification intentionally — it signals no coverage and no successful appeals path without new clinical evidence.

Ovarian vein transposition is a separate issue. The policy lists CPT 64561 and 64581 under the group label "Ovarian vein transposition — no specific code." These are neurostimulator electrode implantation codes, and their appearance in this context signals that there isn't a dedicated CPT code for ovarian vein transposition. Billing these codes for that purpose carries significant claim denial risk.

HCPCS code A4290 — sacral nerve stimulation test lead — is explicitly listed as not covered for indications in this CPB. Don't bill it for PCS.

The pharmacotherapy-related HCPCS codes — J1950, J9202, J9217, J9219 (leuprolide and goserelin formulations), J1110 (dihydroergotamine), and S0132 (ganirelix acetate) — appear in the policy as "other HCPCS codes related to the CPB." These document the pharmacotherapy step. They're relevant to demonstrating failed medical treatment, but they're not the reimbursement target. Understanding how they're used in records supports your documentation strategy when proving criterion two is met.

Coverage Indications at a Glance

Aetna Pelvic Congestion Syndrome Billing Guidelines and Action Items 2025

These are the steps your billing team and clinical documentation staff need to complete. The effective date is September 26, 2025 — if you're reading this after that date, start now.

1. Audit your charge capture for CPT 37241 on active PCS cases.
Pull all open authorizations and pending claims for pelvic congestion syndrome embolization billed under CPT 37241. Confirm that each case has both a qualifying diagnostic imaging report and a documented pharmacotherapy trial in the record. If either is missing, hold the claim.

2. Update your pre-authorization checklist to include both criteria.
Your prior auth request for any PCS embolization needs to show imaging confirmation and failed medical treatment. Build a checklist your schedulers and auth coordinators use before the case goes to the OR or procedure suite. One missed field is a denied claim.

3. Stop billing HCPCS A4290 for PCS indications.
This code is explicitly not covered under CPB 0441. If it's appearing on PCS claims, pull it. If you've submitted recent claims with A4290 for this diagnosis, check for remittances and address any overpayments proactively.

4. Flag CPT 64561 and 64581 for clinical review before billing.
These neurostimulator codes appear under the "ovarian vein transposition — no specific code" group label. That designation means there's no clean coding path for this procedure under this policy. If your interventional radiologists or vascular surgeons perform ovarian vein transposition, talk to your compliance officer before billing 64561 or 64581 for that indication.

5. Build ICD-10 N94.89 into your PCS claim template.
This is the diagnosis code — "other specified conditions associated with female genital organs and menstrual cycle" — that maps to pelvic congestion syndrome under this policy. Make sure your coders use it consistently on claims for CPT 37241 and related catheter placement codes. Diagnosis-to-procedure alignment matters for medical necessity reviews.

6. Train your documentation team on what "failed pharmacotherapy" requires.
Aetna's criteria say "failed a trial of appropriate pharmacotherapy." That language requires your clinical records to show the specific agents tried (e.g., analgesics, hormonal therapy), the duration, and the outcome. Vague notes — "patient failed conservative treatment" — won't hold up in a medical necessity audit. The HCPCS codes J1950, J9202, J9217, J9219, J1110, and S0132 can support documentation of the drug regimen, but the clinical notes need to tell the story.

If you're uncertain how this policy applies to a specific patient mix or procedural setting, loop in your compliance officer before the September 26, 2025 effective date. Pelvic congestion syndrome billing has historically been inconsistent across specialties, and a policy with an "experimental" default for non-qualifying cases creates real exposure.

CPT, HCPCS, and ICD-10 Codes for Pelvic Congestion Syndrome Treatments Under CPB 0441

Covered CPT Codes (When Selection Criteria Are Met)

Not Covered / Flagged Codes

Key ICD-10-CM Diagnosis Code